About Diagnostic Hybrids
Diagnostic Hybrids is a company based in Athens (United States) founded in 1983 was acquired by Quidel in January 2010.. Diagnostic Hybrids has raised $10 million across 1 funding round from investors including Summit Partners, Kenson Ventures and QuidelOrtho. Diagnostic Hybrids offers products and services including QuickVue COVID-19 Test, Sofia Platform, Solana Molecular Testing Platform, and VITROS Systems. Diagnostic Hybrids operates in a competitive market with competitors including ArcherDX, Inscripta, GenScript, OncoDNA and Sino Biological, among others.
- Headquarter Athens, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Quidel Corporation
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$10 M (USD)
in 1 rounds
-
Latest Funding Round
$10 M (USD), Private Equity Round
Aug 11, 2004
-
Investors
Summit Partners
& 2 more
-
Employee Count
Employee Count
-
Acquired by
Quidel
(Jan 10, 2010)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Diagnostic Hybrids
Diagnostic Hybrids offers a comprehensive portfolio of products and services, including QuickVue COVID-19 Test, Sofia Platform, Solana Molecular Testing Platform, and VITROS Systems. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Fast test for detecting COVID-19 at home or point-of-care.
Benchtop system for rapid immunoassay and testing solutions.
Platform for efficient molecular testing in labs.
Systems for clinical chemistry and immunoassay processing.
Funding Insights of Diagnostic Hybrids
Diagnostic Hybrids has successfully raised a total of $10M through 1 strategic funding round. The most recent funding activity was a Private Equity Round round of $10 million completed in August 2004. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Private Equity Round — $10.0M
-
First Round
First Round
(11 Aug 2004)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2004 | Amount | Private Equity Round - Diagnostic Hybrids | Valuation | Summit Partners |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Diagnostic Hybrids
Diagnostic Hybrids has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Summit Partners, Kenson Ventures and QuidelOrtho. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Summit Partners is recognized as a growth equity investment firm.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
QuidelOrtho is engaged in providing diagnostic testing solutions globally.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Diagnostic Hybrids
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Diagnostic Hybrids
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Diagnostic Hybrids Comparisons
Competitors of Diagnostic Hybrids
Diagnostic Hybrids operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ArcherDX, Inscripta, GenScript, OncoDNA and Sino Biological, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| domain | founded_year | HQ Location |
Speech recognition solutions are provided by Inscripta for healthcare professionals.
|
|
| domain | founded_year | HQ Location |
Reagents and instruments are provided for life sciences research.
|
|
| domain | founded_year | HQ Location |
Genomic and theranostic services for oncology precision medicine are delivered.
|
|
| domain | founded_year | HQ Location |
Reagents and kits are provided for clinical research applications.
|
|
| domain | founded_year | HQ Location |
Develops tools and products for research and clinical application
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Diagnostic Hybrids
Frequently Asked Questions about Diagnostic Hybrids
When was Diagnostic Hybrids founded?
Diagnostic Hybrids was founded in 1983 and raised its 1st funding round 21 years after it was founded.
Where is Diagnostic Hybrids located?
Diagnostic Hybrids is headquartered in Athens, United States.
Is Diagnostic Hybrids a funded company?
Diagnostic Hybrids is a funded company, having raised a total of $10M across 1 funding round to date. The company's 1st funding round was a Private Equity Round of $10M, raised on Aug 11, 2004.
What does Diagnostic Hybrids do?
Diagnostic Hybrids develops and manufactures cellular and molecular diagnostic kits for various applications in detecting a range of respiratory diseases, herpes infections, thyroid function, and other markers of diseases. The company offers a D3 FastPoint L-DFA influenza Ainfluenza B virus identification kit, which allows for the identification of influenza A virus and influenza B virus from a patients specimen in under 30 minutes. It also develops and commercializes genetically engineered cell-based detection products for the pharmaceutical and biotechnology industry with a focus on pharmacology assays and products that measure drug clearance and anti-viral interventions with drugs and vaccines.
Who are the top competitors of Diagnostic Hybrids?
Diagnostic Hybrids's top competitors include Sino Biological, OncoDNA and ArcherDX.
What products or services does Diagnostic Hybrids offer?
Diagnostic Hybrids offers QuickVue COVID-19 Test, Sofia Platform, Solana Molecular Testing Platform, and VITROS Systems.
Who are Diagnostic Hybrids's investors?
Diagnostic Hybrids has 3 investors. Key investors include Summit Partners, Kenson Ventures, and QuidelOrtho.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.